Guangdong Hybribio Biotech Co Ltd Working Capital to Net Assets Ratio
Guangdong Hybribio Biotech Co Ltd working capital to net assets ratio. Guangdong Hybribio Biotech Co Ltd (300639) has a Working Capital to Net Assets ratio of 37.1% as of June 2026. Working capital of CN¥1.38 Billion (current assets of CN¥1.70 Billion minus current liabilities of CN¥315.11 Million) is measured against net assets of CN¥3.72 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. Check Guangdong Hybribio Biotech Co Ltd tangible net worth ratio to evaluate the tangible quality of the company's equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of Guangdong Hybribio Biotech Co Ltd (2012–2025)
Working capital to net assets ratio of Guangdong Hybribio Biotech Co Ltd from 2012 to 2025. This chart shows how Guangdong Hybribio Biotech Co Ltd's Working Capital to Net Assets ratio has evolved across 14 annual periods from 2012 to 2025. As of June 2026, the ratio stands at 37.1%, reflecting working capital of CN¥1.38 Billion against net assets of CN¥3.72 Billion CNY. See Guangdong Hybribio Biotech Co Ltd defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Guangdong Hybribio Biotech Co Ltd Working Capital to Net Assets Ratio by Year (2012–2025)
Guangdong Hybribio Biotech Co Ltd working capital to net assets ratio by year from 2012 to 2025. The table below presents the year-by-year Working Capital to Net Assets ratio for Guangdong Hybribio Biotech Co Ltd from 2012 to 2025, covering 14 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see 300639 total asset value.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 42.1% | CN¥1.54 Billion | CN¥3.66 Billion | CN¥1.89 Billion | CN¥352.33 Million | ▼ -2.0 pp |
| 2024 | 44.1% | CN¥1.78 Billion | CN¥4.05 Billion | CN¥2.23 Billion | CN¥441.55 Million | ▼ -8.3 pp |
| 2023 | 52.3% | CN¥2.67 Billion | CN¥5.10 Billion | CN¥3.18 Billion | CN¥507.92 Million | ▼ -5.8 pp |
| 2022 | 58.1% | CN¥3.04 Billion | CN¥5.23 Billion | CN¥4.40 Billion | CN¥1.36 Billion | ▲ +4.2 pp |
| 2021 | 54.0% | CN¥1.87 Billion | CN¥3.48 Billion | CN¥2.55 Billion | CN¥677.59 Million | ▼ -11.5 pp |
| 2020 | 65.5% | CN¥1.66 Billion | CN¥2.53 Billion | CN¥1.96 Billion | CN¥303.02 Million | ▲ +18.3 pp |
| 2019 | 47.1% | CN¥558.41 Million | CN¥1.18 Billion | CN¥664.63 Million | CN¥106.22 Million | ▼ -9.6 pp |
| 2018 | 56.7% | CN¥612.87 Million | CN¥1.08 Billion | CN¥709.31 Million | CN¥96.43 Million | ▼ -6.4 pp |
| 2017 | 63.1% | CN¥612.73 Million | CN¥970.90 Million | CN¥697.25 Million | CN¥84.52 Million | ▲ +25.6 pp |
| 2016 | 37.5% | CN¥188.28 Million | CN¥501.67 Million | CN¥248.91 Million | CN¥60.62 Million | ▲ +2.4 pp |
| 2015 | 35.1% | CN¥145.34 Million | CN¥413.71 Million | CN¥205.67 Million | CN¥60.33 Million | ▼ -20.2 pp |
| 2014 | 55.3% | CN¥190.69 Million | CN¥344.60 Million | CN¥230.35 Million | CN¥39.65 Million | ▼ -6.4 pp |
| 2013 | 61.7% | CN¥118.13 Million | CN¥191.38 Million | CN¥186.06 Million | CN¥67.93 Million | ▲ +9.6 pp |
| 2012 | 52.1% | CN¥67.90 Million | CN¥130.29 Million | CN¥104.53 Million | CN¥36.64 Million | — |